Aberrant activation of mTORC1 signaling in cancer is primarily due to the frequent misregulation of these upstream signaling pathways, which converge to regulate the TSC protein complex (TSC1-TSC2-TBC1D7), a key negative regulator of mTORC12. Here, TSC1 is linked to cancer.